Pharmaceutical stocks extended their remarkable rally on Tuesday, with the Nifty Pharma index rising 1.77 percent to 25,197.55 as of 10:20 AM, marking the fifth consecutive session of gains. The sector has now surged 5.5 percent over this five-session period, significantly outperforming the broader market. According to Business Standard, 19 out of 20 constituents were trading in the green, with Piramal Pharma leading the gains at 9.8 percent at ₹174, followed by Laurus Labs up 3.3 percent at ₹1,482.80. The strength was broad-based across the sector, with Cipla, Biocon, Wockhardt, Gland Pharma, and Ajanta Pharma each gaining between 2-3 percent, while Dr Reddy's, Sun Pharma, Mankind Pharma, Aurobindo Pharma, Torrent Pharma, Lupin, Zydus Life, Glenmark Pharma, Alkem Lab, JB Chemicals and Pharma, and IPCA Lab posted gains of 1-2 percent.
India is grappling with a severe shortage of two cornerstone chemotherapy drugs: cisplatin and carboplatin, according to The Pharma Letter. These drugs, which were first approved in 1978 and 1989 respectively, remain standard of care across multiple tumor types including lung cancer, ovarian cancer, bladder cancer, head and neck cancer, and testicular cancer. The shortage is driven by soaring platinum prices (the primary raw material), higher import duties on platinum-group metals, and regulatory delays that are preventing manufacturers from restarting or scaling production. Indian generic manufacturers report that production has become financially unsustainable at current raw material costs and domestic price controls, as it costs more to produce cisplatin than the regulated price allows.
The US Food and Drug Administration has reached out to Indian pharmaceutical manufacturers for a critical cancer medicine through the Indian Drug Manufacturers' Association (IDMA). According to Mint, the US FDA sent an SOS to the IDMA seeking assistance in identifying manufacturers capable of supplying ifosfamide injection, which is used to treat testicular, bladder and lung cancers. The USFDA prefers FDA-registered facilities but is open to non-registered Indian plants with good compliance history, as reported by CNBC TV18. This represents the second India-specific supply chain disruption covered, following the API rerouting due to Strait of Hormuz closure in May. The drug shortage is caused by a technical disruption at Baxter International's contract manufacturing site and supply chain disruptions due to the West Asia war, with supply expected to remain limited through 2026.
According to Sudeep Shah, head - technical and derivatives research at SBI Securities, the Nifty Pharma index has surpassed its previous swing high of 25,043, recorded on May 20, and has rallied more than 5 percent over the last five trading sessions. The index has also registered a fresh breakout on the weekly chart, signalling a continuation of its bullish trend. The Pharma/Nifty ratio chart has turned favourable, with the ratio line witnessing a strong rebound from its 50-day EMA, indicating continued relative outperformance of the pharma space against the benchmark. The zone of 25,000–25,050 is expected to act as an immediate support area, with the ongoing uptrend likely to remain intact as long as the index sustains above this zone. Ponmudi R, CEO of Enrich Money, noted that the improving outlook for Indian pharmaceutical exporters is attracting buyers, with increasing opportunities in specialty drugs, CDMO, biosimilars and complex generics strengthening investor confidence.
The shortage affects over 2 million new cancer cases estimated in the US in 2025, with India exporting medicines worth ₹75,803.50 crore to the US in FY26, which accounted for about 35% of the country's total medicine exports. If the shortage extends beyond India to affect global supply, US cancer centers could face treatment delays. The FDA's six-month stockpile of 26 essential medicines ordered by the White House in mid-2025 may not include cisplatin and carboplatin specifically. This creates potential opportunities for alternative platinum-based formulations, liposomal delivery systems, or non-platinum chemotherapy backbones, with companies having differentiated manufacturing capabilities gaining competitive advantage. Among the companies likely to benefit are Zydus Lifesciences as a direct beneficiary due to its presence in the ifosfamide segment, Aurobindo Pharma with its strong injectable drugs platform, Dr. Reddy's Laboratories with its oncology APIs and formulations business, and Lupin and Sun Pharma due to their high-potency oncology manufacturing capabilities and scale in oncology and injectable medicines.
